These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand. Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919 [TBL] [Abstract][Full Text] [Related]
7. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Kim DS; Na DG; Kim KH; Kim JH; Kim E; Yun BL; Chang KH Radiology; 2009 May; 251(2):467-75. PubMed ID: 19261924 [TBL] [Abstract][Full Text] [Related]
8. [The clinical features, neuroimaging findings and pathological characteristics of 26 patients with pathologically proven tumor-like inflammatory demyelinating diseases]. Qi XK; Liu JG; Qian HR; Qiu F; Yao S; Li CQ; Wang YM Zhonghua Nei Ke Za Zhi; 2010 Sep; 49(9):750-3. PubMed ID: 21092444 [TBL] [Abstract][Full Text] [Related]
10. [Analysis of pathological characteristics of acute and chronic cerebral tumefactive demyelinating lesions]. Sun C; Liu J; Gui Q; Lu D; Qi X Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(45):3557-61. PubMed ID: 25622833 [TBL] [Abstract][Full Text] [Related]
11. Tumefactive demyelinating lesions: A comprehensive review. Algahtani H; Shirah B; Alassiri A Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436 [TBL] [Abstract][Full Text] [Related]
12. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. Siri A; Carra-Dalliere C; Ayrignac X; Pelletier J; Audoin B; Pittion-Vouyovitch S; Debouverie M; Lionnet C; Viala F; Sablot D; Brassat D; Ouallet JC; Ruet A; Brochet B; Taillandier L; Bauchet L; Derache N; Defer G; Cabre P; de Seze J; Lebrun Frenay C; Cohen M; Labauge P J Neurol; 2015 Jul; 262(7):1637-45. PubMed ID: 25929666 [TBL] [Abstract][Full Text] [Related]
13. Tumour-like lesions in multiple sclerosis. Jamroz-Wiśniewska A; Janczarek M; Belniak E; Stelmasiak Z; Bartosik-Psujek H Neurol Neurochir Pol; 2008; 42(2):161-7. PubMed ID: 18512174 [TBL] [Abstract][Full Text] [Related]
17. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions. Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721 [TBL] [Abstract][Full Text] [Related]
18. Tumefactive Demyelinating Lesions in Children: A Rare Case of Conus Medullaris Involvement and Systematic Review of the Literature. Pérez CA; Patnaik A; Oommen S; Redko A; Mathis SB J Child Neurol; 2020 Sep; 35(10):690-699. PubMed ID: 32552343 [TBL] [Abstract][Full Text] [Related]
19. Neuroimaging and clinicopathological differences between tumefactive demyelinating lesions and sentinel lesions of primary central nervous system lymphoma. Sun C; Han J; Lin Y; Qi X; Li C; Liu J; Qiu F Front Immunol; 2022; 13():986473. PubMed ID: 36059526 [TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology. Saridas F; Mesut G; Ceylan CY; Ozpar R; Ozsen M; Koc ER; Tolunay S; Hakyemez B; Turan OF Mult Scler Relat Disord; 2024 May; 85():105537. PubMed ID: 38460252 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]